<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01797484</url>
  </required_header>
  <id_info>
    <org_study_id>UHZ-KARD-01-2013</org_study_id>
    <nct_id>NCT01797484</nct_id>
  </id_info>
  <brief_title>Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia</brief_title>
  <acronym>RIMINI-Pilot</acronym>
  <official_title>Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the RIMINI-Trial is to examine the effect of Ranolazine on ischemic myocardium in
      acute myocardial ischemia.

      A pilot-trial by Venkatamaran et al. recently demonstrated, that the area of ischemic
      myocardium in patients with stable coronary artery disease can be reduced by
      Ranolazine-treatment2. This effect was shown by significantly reduced areas of atypical or
      dysfunctional myocardium in SPECT-examinations.

      The dimension of myocardial damage (i.e. area of ischemic myocardium) is directly related to
      the rate of complications (i.e. left-ventricular pump failure, malignant arrhythmia) and the
      grade of Rehabilitation to daily life (i.e. persistent reduced left-ventricular ejection
      fraction).

      In patients with stable angina pectoris, Ranolazine is used with beneficial results1.
      Ranolazine improves diastolic blood flow and therefore microcirculation in the myocardium by
      reducing diastolic tension (via inhibiting late Na+-Influx and consecutive Ca2+-Overload).

      Recently published data2 showed that treatment with Ranolazine significantly reduces the
      ischemic area in chronic damaged myocardium. This is due the effect of improved
      microcirculation in hibernating myocardium.

      Early administration of Ranolazine and improvement of microcirculation in patients with acute
      damaged myocardium (i.e. directly after acute ischemia) should lead to a recruitment and
      re-uptake of cardiac activity of hibernating myocardium.

      For the RIMINI-Trial patients are given Ranolazine on top of the guideline-based treatment to
      reduce the area of acute ischemic myocardium.

      Patients with unstable angina pectoris and proof of acute cardiac ischemia, proof of
      myocardial dyskinesia and angina pectoris in the patient history will receive unaltered
      guideline-based therapy for acute cardiac ischemia5,6. All necessary procedures will be
      performed to stabilize patients to a hemodynamically compensated state and patients are then
      transferred to receive cardiac catheterization (angiography and angioplasty if necessary).

      After patients are stabilized Ranolazine will be given additionally to guideline based
      medication.

      The measurement of the ischemic myocardial area will be done via three functional
      echocardiographies with speckle tracking technique10.

      A statistical evaluation of ischemic myocardial area before and after treatment with
      Ranolazine/Placebo will be done after conclusion of the RIMINI-Trial to show the effect of
      Ranolazine in acute myocardial ischemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the RIMINI-Trial is to examine the effect of Ranolazine on ischemic myocardium in
      acute myocardial ischemia.

      A pilot-trial by Venkatamaran et al. recently demonstrated, that the area of ischemic
      myocardium in patients with stable coronary artery disease can be reduced by
      Ranolazine-treatment2. This effect was shown by significantly reduced areas of atypical or
      dysfunctional myocardium in SPECT-examinations.

      The dimension of myocardial damage (i.e. area of ischemic myocardium) is directly related to:

        1. Rate of complications (i.e. left-ventricular pump failure, malignant arrhythmia)

        2. Grade of Rehabilitation to daily life (i.e. persistent reduced left-ventricular ejection
           fraction)

      Early angioplasty and coronary medication are key factors for preventing complications and
      ensuring sufficient rehabilitation. This is done to reduce the ischemic area as best as
      possible.

      In patients with stable angina pectoris, Ranolazine is used with beneficial results1.
      Ranolazine improves diastolic blood flow and therefore microcirculation in the myocardium by
      reducing diastolic tension (via inhibiting late Na+-Influx and consecutive Ca2+-Overload).

      Recently published data2 showed that treatment with Ranolazine significantly reduces the
      ischemic area in chronic damaged myocardium. This is due the effect of improved
      microcirculation in hibernating myocardium.

      Early administration of Ranolazine and improvement of microcirculation in patients with acute
      damaged myocardium (i.e. directly after acute ischemia) should lead to a recruitment and
      re-uptake of cardiac activity of hibernating myocardium.

      For the RIMINI-Trial patients are given Ranolazine on top of the guideline-based treatment to
      reduce the area of acute ischemic myocardium.

      Patients with unstable angina pectoris and proof of acute cardiac ischemia (Serum levels of
      Troponin-T-hs &gt;14 pg/ml), proof of myocardial dyskinesia and angina pectoris &gt;/=CCS II
      (Canadian Cardiovascular Society Classification of Angina Pectoris) in the patient history
      will receive unaltered guideline-based therapy for acute cardiac ischemia5,6. All necessary
      procedures will be performed to stabilize patients to a hemodynamically compensated state
      (normalized levels of blood pressure, heart rate, absent malignant arrhythmia, dyspnoea and
      angina-like symptoms), and patients are then transferred to receive cardiac catheterization
      (angiography and angioplasty if necessary).

      After patients are stabilized (i.e. via angioplasty, medical treatment) Ranolazine will be
      given additionally to guideline-based medication (Beta-Blocker, ACE-Inhibitor or
      AT1-Inhibitor, ASS, Clopidogrel, Statins).

      The measurement of the ischemic myocardial area will be done via three functional
      echocardiographies with speckle tracking technique10 (speckle -tracking echocardiography,
      SPE):

        1. The first speckle tracking for screening and will be done directly with patients
           presenting in the emergency room.

        2. After stabilization and coronary angiography or -plasty and before the first dose of
           Ranolazine is given, the second speckle tracking will be done for baseline.

        3. After 42 days of Ranolazine-treatment the third and final speckle tracking
           echocardiography will be done.

      A statistical evaluation of ischemic myocardial area before and after treatment with
      Ranolazine/Placebo will be done after conclusion of the RIMINI-Trial to show the effect of
      Ranolazine in acute myocardial ischemia.

      For controlling and comparing the effect, the RIMINI-Trial will be single-blinded and
      compared to a group of patients not treated with Ranolazine. Participants will be randomized
      to the treatment-group or the no-treatment-group using a computer based randomization-method.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricular Global Strain Rate</measure>
    <time_frame>42 days after first dose of Ranolazine</time_frame>
    <description>Relativ acceleration or deceleration (1/s) of left ventricular myocardial sections compared to direct opposite section. The more positive the value, the more simultaneously the movements, the more hemodynamically better.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Acute Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranolazine 500mg bid orally 7 days Ranolazine 750mg bid orally 35 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No additional medication</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No additional medication - control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Improvement of myocardial microcirculation</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Proof of acute cardiac ischemia by elevated serum Troponin T-hs levels &gt; 14 pg/nl

          -  Proof of myocardial dyskinesia with functional echocardiography (&quot;speckle tracking&quot;)

          -  Stable angina pectoris &gt;/= CCS II in patient history

          -  Stabilized (i.e. normalized vital parameters) patients after coronary angioplasty or
             angiography

          -  Coronary angioplasty or angiography not older than 24 hours

          -  Written informed consent

          -  Established standard therapy for coronary artery disease (i.e. Beta-Blocker,
             ACE-Inhibitor or AT1-Inhibitor, ASS, Clopidogrel, Statins)

        Exclusion Criteria:

          -  Patients younger than 18 years of age

          -  Acute cardio-pulmonary decompensation

          -  Middle and high grade liver insufficiency (Child-Pugh Score B and C)

          -  High grade renal insufficiency (Creatinine-Clearance &lt; 30 ml/min)

          -  Concomitant treatment with potent inhibitors of CYP3A4

          -  Concomitant administration of class Ia (e.g. quinidine) or class III (e.g. dofetilide,
             sotalol) antiarrhythmics, except for amiodarone

          -  Concomitant administration of &gt; 20 mg simvastatin/day

          -  Patients with heart failure classification NYHA III and NYHA IV

          -  Homeless patients and drug-addicted patients

          -  Pregnant and/or breast-feeding women

          -  Treatment with Ranolazine prior to enrolment in RIMINI-Trial

          -  Allergy against Ranolazine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Blankenberg, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of University Heart Center Hamburg Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Heart Center Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.uhz.de</url>
    <description>University Heart Center Hamburg Eppendorf</description>
  </link>
  <reference>
    <citation>Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, Wolff AA, Skene A, McCabe CH, Braunwald E; MERLIN-TIMI 36 Trial Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007 Apr 25;297(16):1775-83.</citation>
    <PMID>17456819</PMID>
  </reference>
  <reference>
    <citation>Venkataraman R, Belardinelli L, Blackburn B, Heo J, Iskandrian AE. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images. JACC Cardiovasc Imaging. 2009 Nov;2(11):1301-9. doi: 10.1016/j.jcmg.2009.09.006.</citation>
    <PMID>19909934</PMID>
  </reference>
  <reference>
    <citation>El-Kadri M, Sharaf-Dabbagh H, Ramsdale D. Role of antiischemic agents in the management of non-ST elevation acute coronary syndrome (NSTE-ACS). Cardiovasc Ther. 2012 Feb;30(1):e16-22. doi: 10.1111/j.1755-5922.2010.00225.x. Epub 2010 Sep 15. Review.</citation>
    <PMID>20840192</PMID>
  </reference>
  <reference>
    <citation>Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008 Dec;29(23):2909-45. doi: 10.1093/eurheartj/ehn416. Epub 2008 Nov 12.</citation>
    <PMID>19004841</PMID>
  </reference>
  <reference>
    <citation>Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007 Jul;28(13):1598-660. Epub 2007 Jun 14.</citation>
    <PMID>17569677</PMID>
  </reference>
  <reference>
    <citation>Andersen GØ, Knudsen EC, Aukrust P, Yndestad A, Oie E, Müller C, Seljeflot I, Ueland T. Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. Heart. 2011 Mar;97(6):460-5. doi: 10.1136/hrt.2010.206714. Epub 2011 Jan 26.</citation>
    <PMID>21270073</PMID>
  </reference>
  <reference>
    <citation>Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Grøgaard HK, Bjørnerheim R, Brekke M, Müller C, Hopp E, Ragnarsson A, Brinchmann JE, Forfang K. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006 Sep 21;355(12):1199-209.</citation>
    <PMID>16990383</PMID>
  </reference>
  <reference>
    <citation>Miller TD, Gibbons RJ. Measuring myocardium at risk in acute myocardial infarction--a continuing challenge. J Nucl Cardiol. 2010 Oct;17(5):778-80. doi: 10.1007/s12350-010-9278-3.</citation>
    <PMID>20717762</PMID>
  </reference>
  <reference>
    <citation>Geyer H, Caracciolo G, Abe H, Wilansky S, Carerj S, Gentile F, Nesser HJ, Khandheria B, Narula J, Sengupta PP. Assessment of myocardial mechanics using speckle tracking echocardiography: fundamentals and clinical applications. J Am Soc Echocardiogr. 2010 Apr;23(4):351-69; quiz 453-5. doi: 10.1016/j.echo.2010.02.015. Erratum in: J Am Soc Echocardiogr. 2010 Jul;23(7):734.</citation>
    <PMID>20362924</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2013</study_first_submitted>
  <study_first_submitted_qc>February 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2013</study_first_posted>
  <results_first_submitted>April 25, 2016</results_first_submitted>
  <results_first_submitted_qc>January 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 12, 2018</results_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Tjark Frederik Schwemer</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>ischemia</keyword>
  <keyword>myocardium</keyword>
  <keyword>Ranolazine</keyword>
  <keyword>dyskinesia</keyword>
  <keyword>speckle tracking echocardiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>first patient enrolled: 05-Aug-2013 last patient finished: 05-Jun-2015
All patients were enrolled at University Heart Centre Hamburg Eppendorf</recruitment_details>
      <pre_assignment_details>n.a.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ranolazine</title>
          <description>Ranolazine 500mg bid orally 7 days Ranolazine 750mg bid orally 35 days
Ranolazine: Improvement of myocardial microcirculation</description>
        </group>
        <group group_id="P2">
          <title>No Additional Medication</title>
          <description>No additional medication - control group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ranolazine</title>
          <description>Ranolazine 500mg bid orally 7 days Ranolazine 750mg bid orally 35 days
Ranolazine: Improvement of myocardial microcirculation</description>
        </group>
        <group group_id="B2">
          <title>No Additional Medication</title>
          <description>No additional medication - control group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="9"/>
                    <measurement group_id="B2" value="72" spread="7"/>
                    <measurement group_id="B3" value="70" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Left Ventricular Global Strain Rate</title>
        <description>Relativ acceleration or deceleration (1/s) of left ventricular myocardial sections compared to direct opposite section. The more positive the value, the more simultaneously the movements, the more hemodynamically better.</description>
        <time_frame>42 days after first dose of Ranolazine</time_frame>
        <population>Secondary Outcome Measure data was not collected. Initially planned secondary outcome (e.g. cardiac events) was found to interfere with monitoring drug safety</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Ranolazine 500mg bid orally 7 days Ranolazine 750mg bid orally 35 days
Ranolazine: Improvement of myocardial microcirculation</description>
          </group>
          <group group_id="O2">
            <title>No Additional Medication</title>
            <description>No additional medication - control group</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Global Strain Rate</title>
          <description>Relativ acceleration or deceleration (1/s) of left ventricular myocardial sections compared to direct opposite section. The more positive the value, the more simultaneously the movements, the more hemodynamically better.</description>
          <population>Secondary Outcome Measure data was not collected. Initially planned secondary outcome (e.g. cardiac events) was found to interfere with monitoring drug safety</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="2"/>
                    <measurement group_id="O2" value="23" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ranolazine</title>
          <description>Ranolazine 500mg bid orally 7 days Ranolazine 750mg bid orally 35 days
Ranolazine: Improvement of myocardial microcirculation</description>
        </group>
        <group group_id="E2">
          <title>No Additional Medication</title>
          <description>No additional medication - control group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Tjark F. Schwemer</name_or_title>
      <organization>University Heart Centre Hamburg Eppendorf</organization>
      <phone>+49 40 7410 ext 56800</phone>
      <email>t.schwemer@uke.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

